Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT04815785
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 120 participants
- Sponsor
- Fu Wai Hospital, Beijing, China
- General Hospital of Shenyang Military Region
- Peijia Medical Technology (Suzhou) Co., Ltd.
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Second Xiangya Hospital of Central South University
- The Second Affiliated Hospital of Harbin Medical University
- West China Hospital
- Registry
-
NCT04815785
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT04815785. Allocation not applicable; no masking; primary purpose treatment. Start 2017-09-22 (actual); primary completion 2020-05-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis
- Condition
- Aortic Stenosis
- Intervention (Device)
- TaurusOne® transcatheter aortic valve replacement system
- Lead sponsor
- Peijia Medical Technology (Suzhou) Co., Ltd.
- Collaborator
- Fu Wai Hospital, Beijing, China
- Collaborator
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Collaborator
- West China Hospital
- Collaborator
- General Hospital of Shenyang Military Region
- Collaborator
- The Second Affiliated Hospital of Harbin Medical University
- Collaborator
- Second Xiangya Hospital of Central South University
Record details
- Record id
cardio:ct-nct04815785- Content hash
24f363241f271ef5ee2a8c41a8adde4b5d62724dd49132429d47437850dd35c2